The long-running debate over ADHD reached boiling point in Britain this August, when Channel 4, one of the country’s main public-service broadcasters, aired The Great ADHD Myth?¹ Presented by Dr Max Pemberton, a psychiatrist in Britain’s National Health Service, the one-hour documentary drew on expert interviews to examine whether ADHD is a genuine neurodevelopmental disorder or a social construct, and whether the rapid growth in diagnosis and stimulant use reflects illness or the demands of modern life. It also followed one family as their son temporarily stopped taking medication and adopted a range of lifestyle changes.

The reaction began even before the documentary aired. ADHD UK, a registered charity whose stated aims include “providing accurate, pertinent, quality information for people with ADHD”, sent Channel 4 an open letter warning that the programme’s title and framing would cause harm.² After the broadcast, it complained to Britain’s broadcasting regulator and encouraged viewers to do the same. It also published a fierce response criticising the programme’s on-screen experiment and warning that the broadcast would intensify stigma, deter people from seeking assessment and treatment, and put lives at risk.

These are serious allegations and deserve careful consideration. Objections to the programme’s presentation, however, must be judged against the limits of the medium. In less than an hour, the documentary brought a suppressed perspective on a major issue in children’s health into public view. Of course it relied on story and emotion. Of course it edited and condensed its expert interviews. That is what television does. But ADHD UK went well beyond such criticism. Its response made three far-reaching, categorical claims about ADHD and the state of the science that demand closer scrutiny:

1. “ADHD is not scientifically controversial.”
2. “This is not a parlour debate. People die.”
3. “ADHD is not a myth. It is not a social construct.”

Together, these declarations portray the science surrounding ADHD as settled. Claims this broad call for a much fuller examination than ADHD UK could offer in a brief public statement, or than I can offer in a short response here. A serious assessment must address the philosophical foundations of psychiatric diagnosis in the absence of independent diagnostic biomarkers, the reliability and validity of the ADHD diagnosis itself, and the long-term evidence for the efficacy and safety of the medications recommended as first-line treatment. That is the larger task I took on in my book, ADHD Is Not an Illness and Ritalin Is Not a Cure.³

My purpose here is narrower. I will put each of ADHD UK’s three declarations to the test using a small number of central examples. Just one brief note before we begin. There is an unavoidable tension in summarising the case I am about to make in a few sentences, since my central point is that claims this sweeping require careful evidence and analysis. Still, it may help to set out the core of the argument before working through the evidence:

First, a decades-long and often fierce scientific controversy cannot be ended by declaring that no controversy exists. Second, an association between an ADHD diagnosis and premature death cannot show that ADHD itself is responsible for the mortality gap when major alternative explanations were not adequately examined, particularly when the first-line treatment for ADHD consists of stimulant medications with documented cardiovascular and psychiatric risks relevant to premature mortality. Finally, the declaration that ADHD is neither a myth nor a social construct ultimately rests on a much larger proposition: that ADHD is a valid and distinct medical or neurobiological condition. That proposition requires a body of evidence far beyond what ADHD UK could reasonably present in a brief response, and far beyond what I can fully examine here. But even a limited examination of one fundamental problem, the extraordinarily high rates of diagnosis in relation to the basic criterion of deviance, is enough to expose a serious problem at the very foundation of the diagnosis.

1. Is There Really No Scientific Controversy?

Only days after the documentary was broadcast, psychiatrist and researcher Dr Joanna Moncrieff published “How to Think About ADHD”.⁴ Her essay deserves to be read in full. Moncrieff asks how ADHD can be presented as a consistent, lifelong neurodevelopmental condition when no specific neurological state or process, and no promising biomarker, has been identified. She also asks why the overlapping but non-identical sets of behaviours labelled ADHD in children and adults should be assumed to reflect a single underlying condition. Readers may disagree with her conclusions. The questions themselves are unmistakably scientific.

Nor did this debate begin last week. Moncrieff’s essay belongs to a long tradition of critical scholarship on ADHD in the United Kingdom. The depth and longevity of this controversy are documented in historian Matthew Smith’s aptly titled book, Hyperactive: The Controversial History of ADHD.⁵ One striking example appeared in 2004, when psychiatrist Sami Timimi led a detailed peer-reviewed critique⁶ of the 2002 “International Consensus Statement on ADHD”.⁶ Timimi and 33 co-endorsers, including Moncrieff, challenged the statement’s biological determinism and dogmatic tone, arguing that it was “completely counter to the spirit and practice of science to cease questioning the validity of ADHD”.⁷

If anything, their critique was restrained compared with the statement’s own categorical and inflammatory language. “There is no such disagreement,” it declared, while claiming that “to publish stories that ADHD is a fictitious disorder… is tantamount to declaring the earth flat, the laws of gravity debatable, and the periodic table in chemistry a fraud”.⁶ Whatever one thinks of the critics’ conclusions, this was scientific disagreement by definition.

Doubt was also visible within the alleged scientific consensus. At the 1998 US National Institutes of Health Consensus Development Conference, Dr. Keith Conners, one of the central architects of modern ADHD research, observed that the wealth of neuroimaging findings had produced little understanding of a neurological basis specific to ADHD.⁸ The high rates of comorbidity, he added, raised questions about the specificity of the diagnosis itself.

In the years that followed, the controversy only intensified.⁹ More than a decade later, Conners himself described soaring diagnosis rates as “a national disaster of dangerous proportions”.¹⁰ He called the numbers preposterous and said: “This is a concoction to justify the giving out of medication at unprecedented and unjustifiable levels.” Conners was not alone. Leon Eisenberg, another foundational figure in the history of ADHD research, was quoted as calling ADHD “a prime example of a fabricated disease”.¹¹ He urged child psychiatrists to spend more time investigating possible psychosocial causes of behavioural problems, including parental conflict and other family problems. Such questions take time, he observed. A pill can be prescribed quickly.

Eisenberg’s concerns were also present in his scholarly writing. In a 2007 historical reflection, he recalled that ADHD did not exist as a diagnosis when he graduated from medical school in 1946.¹² Children with similar behaviours were classified in other ways, and some early researchers were uneasy with labels that implied damaged brain tissue. He wrote that none of them had anticipated the later explosion in diagnosis and stimulant treatment. He questioned the use of stimulant response as confirmation of the diagnosis, asked whether imprecise cut-offs had arbitrarily turned large sections of the population into clinical cases, and wondered whether clinicians armed with stimulants had begun to see every problem as a nail.

Over the years, a growing number of other established scholars joined the founding figures of modern ADHD in raising similar concerns. Neurologist Richard Saul made his position plain in the title of his book, ADHD Does Not Exist,¹³ arguing that behaviours grouped under the ADHD label can stem from numerous medical and psychological conditions (a problem of discriminant validity that I examine in depth in Chapter 5 of my book). Developmental psychologist Jerome Kagan was equally blunt, calling ADHD “an invention” and disputing the claim that most diagnosed children have an underlying dopamine abnormality.¹⁴ Psychologist and educator Thomas Armstrong titled his book The Myth of the ADHD Child,¹⁵ years before Channel 4 framed a similar proposition far more cautiously as a question. These are only three among dozens of recognised clinicians and researchers whose critiques I survey in the Introduction to my book.

Nor did high-profile neurobiological research settle the matter. In 2017, a large Lancet Psychiatry brain-volume study declared that people with ADHD had “altered brains” and that ADHD was therefore “a disorder of the brain”.¹⁶ A published response co-authored by Conners and Allen Frances, who chaired the DSM-IV Task Force, argued that this conclusion was unsupported by the study’s own findings and was “wildly speculative and dangerously misleading at a time when ADHD is already overdiagnosed and overtreated with medication in high-income and middle-income countries”.¹⁷ The controversy was also documented at the time by Peter Simons in Mad in America,¹⁸ and I later revisited the study in a peer-reviewed article, where I subjected its central conclusion to a detailed methodological critique.¹⁹

Frances has been equally blunt about adult ADHD. In a recent essay titled Containing the Adult ADHD Fad, he wrote that “most of what looks like adult ADHD is not adult ADHD”.²⁰ This is not to suggest that either Frances or Conners denies the existence of ADHD. Their criticism has focused primarily on what they regard as widespread and unjustified overdiagnosis. And on that point, they are far from marginal. Concern about ADHD overdiagnosis extends well into mainstream medicine.²¹

A study of hundreds of Israeli physicians specialising in neurology, psychiatry and child development found that most believed unreliable diagnoses of ADHD (as well as ASD) had increased substantially.²² These physicians did not question the existence of ADHD. But widespread diagnostic unreliability is not merely a matter of occasional mistakes. In psychiatry, where no independent biological test can correct such errors, it reaches into the validity of the diagnosis itself. I return to this major problem in Section 3.

The wider critical literature goes further still. Some critics have explicitly called for ADHD to be removed from the DSM, psychiatry’s most influential diagnostic manual.³ Others warn against medicalising ordinary childhood behaviours and using powerful drugs to manage problems that may be educational rather than medical.^23,24 These critics do not need to be right for the controversy to be real. ADHD UK may reject their arguments. What it cannot do is erase a scientific controversy by declaring one side unscientific.

2. Do People Diagnosed with ADHD Die Prematurely (and If So, Why)?

ADHD UK raises the stakes considerably with its second categorical claim: “This is not a parlour debate. People die.” To support this alarming statement, it cited a large UK study of 30,039 adults with a recorded ADHD diagnosis and 300,390 matched controls.²⁵ The researchers estimated that life expectancy was almost seven years shorter for diagnosed men and almost nine years shorter for diagnosed women.

What ADHD UK did not tell its readers is that the same journal had already published my critique of that study.²⁶ My central criticism was simple. The study reported an association between an ADHD label in medical records and shorter estimated life expectancy, but did not include the measures or analyses needed to determine whether ADHD itself accounted for that association or whether more direct explanations did. It therefore could not establish why diagnosed adults appeared to die earlier. Indeed, the researchers themselves wrote that they “believe that this is unlikely to be because of ADHD itself” and instead suggested that the gap was “likely caused by modifiable factors such as smoking, unmet mental and physical health support, and unmet treatment needs”.

What is striking is that the researchers recognised this uncertainty but did not test any of the explanations they themselves offered. They did not examine the role of one of the most basic factors in mortality research: participants’ social and economic circumstances. They justified this omission by arguing that socioeconomic status “is best understood as part of the causal pathway between ADHD and premature mortality”. But that is a hypothesis, not a finding, and it does not remove the need to test the proposed pathway. A more direct explanation therefore remains open: social and economic disadvantage may account for much of the mortality gap, quite apart from ADHD.

This omission is even harder to understand in light of the previous literature on this topic. A major review describing ADHD as associated with “elevated morbidity and mortality” also acknowledged that “the life expectancy of individuals with ADHD… has not been characterized… Instead, studies addressing ADHD-related mortality issues have focused largely on the potential contributions of (a) treatment-related sudden death and (b) suicide”.²⁷ The UK study on mortality neither examined nor even acknowledged these two possibilities.

This matters because mortality risks associated with the first-line treatment for ADHD are clearly not direct consequences of the diagnosis itself. They also cast a very different light on the researchers’ suggestion that the mortality gap is “likely caused by modifiable factors such as… unmet treatment needs”. If stimulant treatment itself increases mortality risk, prescribing more of it could make matters worse. That possibility changes the meaning of “unmet treatment needs” completely.

Importantly, this is not an obscure possibility. The first-line drugs prescribed for ADHD are stimulants. They activate the sympathetic nervous system and raise heart rate and blood pressure.^28,29 Studies in adults have reported associations with serious cardiovascular events, heart failure and cardiomyopathy.^30-32 One case-control study reported a sevenfold association between stimulant use and sudden unexplained death among young people.³³

Then there is suicide. An analysis of the Adolescent Brain Cognitive Development study reported 32% higher odds of suicidality among children taking ADHD medication.³⁴ A large Dutch study found that adults who started methylphenidate were twice as likely to attempt suicide as a demographically similar comparison group.³⁵ Suicidal thoughts and behaviours have also appeared as adverse outcomes in experimental studies.^36,37 Correspondingly, an official UK patient information leaflet warns that “up to 1 in 100 people” taking Concerta XL (a common methylphenidate-based medication for ADHD), may experience thoughts of self-harm or suicide.³⁸

I am not arguing that these findings prove that medication use drove the mortality gap in the UK study. My point is that medication use cannot simply be ignored. In their reply to my critique, the researchers said that their aim was only to estimate the overall difference in life expectancy.³⁹ They also pointed to a Swedish observational study that associated initiation of ADHD medication with lower two-year mortality.⁴⁰ Fair enough. That study belongs in the discussion. So do the many studies reporting cardiovascular, psychiatric and mortality-related risks associated with stimulant treatment (see Chapter 11 of my book). The literature does not speak with one voice.

Even if the Swedish finding is entirely correct, it cannot fill the gap in the UK study. That study still combined medicated and unmedicated adults in the same group. When studying premature death, that distinction is essential. The frightening phrase “People die” cannot erase it.

3. Is ADHD a Valid Medical Diagnosis?

ADHD UK’s third claim is the broadest of all: “ADHD is not a myth. It is not a social construct.” But the word myth does little scientific work here, and describing a diagnosis as a social construct does not mean that the behaviours or suffering associated with it are imaginary. Children can be highly energetic, impulsive or inclined towards a less focused style of thinking. No serious critic denies that they may struggle or suffer, especially when these characteristics conflict with the expectations of schools, families and society. The scientific question is whether grouping these characteristics and difficulties under a single medical label produces a reliable and valid diagnosis.

ADHD UK’s response does not answer that question. To be fair, the issue is too broad for a brief response, an hour-long documentary or even the short article you are reading now. But that is precisely why a categorical declaration cannot substitute for analysis. In the concluding discussion of my book, I identified 75 gaps in the scientific foundations of the ADHD diagnosis and its first-line treatment.³ Some concern weak neurobiological evidence and contradictions within the diagnosis itself. Others concern the absence of convincing evidence for long-term benefit and the known and suspected risks of stimulant treatment. Any single gap may invite a reply. The cumulative case is much harder to dismiss. To offer a sense of what that cumulative case entails, let me look more closely at the fundamental challenge that troubled the founding figures of modern ADHD whom we encountered in Section 1: the soaring rates of ADHD diagnosis.

How High Are ADHD Diagnosis Rates?

When the diagnosis first appeared in its modern form in DSM-III in 1980, the manual already described it as “common”, estimating that it “may occur in as many as 3% of prepubertal children”.⁴¹ By DSM-5-TR, the figure reported in the manual had more than doubled to approximately 7.2% of children. In real-world settings, recorded diagnosis rates can be even higher. In the US, for example, official data indicated that nearly 20% of adolescent boys had received an ADHD diagnosis.^42,43 In Israel, my own country, medical records analysed in a 2020 study showed that more than 20% of the children and young adults in its sample had a formally recorded ADHD diagnosis.⁴⁴ My own retrospective surveys, which captured diagnoses received over time rather than at a single point, yielded even higher cumulative rates.¹⁹ No wonder a recent Nature News Feature put the issue plainly in its title: “ADHD diagnoses are growing. What’s going on?”⁴⁵

Some researchers argue that careful standardised assessment places the underlying prevalence at around 5% in the UK.⁴⁶ Perhaps so. But that does not make the much higher rates elsewhere disappear. It creates a dilemma:

If the Higher Rates Are Real

Suppose the higher figures are accurate and 15% or even 20% of children genuinely have ADHD. We would then need to explain the dramatic rise in diagnosis over only a few decades. If the underlying condition itself increased, human biology appears to have changed at extraordinary speed. If children did not change but their environments and the way their behaviour is judged did, then the social context is part of what turns those behaviours into a disorder. This is vividly illustrated by the dozens of relative-age studies showing that simply being younger than one’s classmates increases the likelihood of receiving an ADHD diagnosis and a stimulant prescription.⁴⁷

Defenders of the biomedical narrative might reply that ADHD was always this common and that the higher rates merely correct decades of underdiagnosis. Even if that were true, rates this high force us to confront a fundamental diagnostic principle: the threshold of deviance.⁴⁸ Because ADHD has no independent biological test, the diagnosis depends entirely on where this boundary is drawn. If the behaviours do not depart meaningfully from ordinary variation, they are not pathological. They are simply human behaviours. If one child in five meets the criteria, the category reaches deep into ordinary human variation. Calling ADHD a common disorder does not solve the problem. It leaves us asking why behaviours shared by so many children should count as pathological at all.

If the 5% Estimate Is Correct

Now suppose the accepted prevalence estimate of about 5% is correct. In places where 15% to 20% of children have been diagnosed, most would have received a lifelong neuropsychiatric diagnosis without justification. For every one “correct” diagnosis, doctors would have given two or three incorrect ones. The diagnostic system would be wrong more often than it was right.

Assuming that clinicians made these diagnoses in good faith, applying the diagnostic criteria as they understood them, such widespread errors cannot be dismissed as careless practice or occasional mistakes. They suggest that the definition itself does not reliably distinguish those who supposedly have ADHD from those who do not.

The implications are profound because of how psychiatric diagnosis works. Unlike many diagnoses in other areas of medicine, ADHD cannot be checked against an independent biological test or disease process. Its behavioural criteria do not merely help clinicians identify a disorder established by other means. They define who has the disorder. If those criteria fail, there is no external standard to correct them. For ADHD, the definition is all we have. If it fails, the validity of the diagnosis fails with it (see Chapters 1 and 2 of my book for a fuller discussion).

Nor can this problem be solved by insisting that a smaller group of children has “real ADHD”. That narrower condition must first be defined and validated in its own right. Until then, “real ADHD” is merely the name of an unspecified hypothetical disorder, not a rescue for the diagnosis currently in use.

Conclusion: Certainty Cannot Repair Flawed Science

The prevalence dilemma, discussed last, has far-reaching implications for the validity of the ADHD diagnosis (Section 3). The harms attributed to ADHD, including premature mortality, are also contested. Some may even reflect adverse effects of the stimulant medications commonly used to treat it (Section 2). And the scientific challenge to the diagnosis has persisted for decades, often in unusually stark terms, including from some of the field’s most senior figures and foundational architects (Section 1). Taken together, these problems suggest that the “biomedical consensus” rests on a much less secure foundation than its categorical public presentation implies.

Children and adults who struggle with attention, restlessness or impulsivity deserve understanding and effective help. Their difficulties are real. But real difficulties do not, by themselves, validate a particular medical diagnosis, nor do they establish the long-term safety and value of its first-line treatment. If a diagnostic category cannot clearly distinguish disorder from ordinary human variation, and if major questions about its treatment remain unresolved, the burden of proof lies with those who present it as established medical fact.

ADHD UK is entitled to criticise the documentary’s editing, framing and on-screen experiment. But its categorical declarations do not answer these scientific problems. It has responded to a television documentary. It has not answered the scientific case against treating ADHD as a settled and validated biomedical diagnosis, or stimulant medication as a scientifically established solution.

***

Bibliography

1. Channel 4. The great ADHD myth? https://www.channel4.com/programmes/the-great-adhd-myth. Updated 2026. Accessed Aug 23, 2026.
2. ADHD UK. Challenging channel 4’s “the great ADHD myth?” – ADHD UK. https://adhduk.co.uk/challenging-c4-the-great-adhd-myth/. Updated 2026. Accessed Aug 22, 2026.
3. Ophir Y. ADHD is not an illness and ritalin is not a cure: A comprehensive rebuttal of the (alleged) scientific consensus. World Scientific; 2022. 10.1142/12752.
4. Moncrieff J. How to think about ADHD. 2026. https://joannamoncrieff.wordpress.com/2026/08/21/how-to-think-about-adhd/. Accessed Aug 23, 2026.
5. Smith M. Hyperactive: The controversial history of ADHD. Reaktion books; 2013.
6. Barkley RA. International consensus statement on ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(12):1389.
7. Timimi S, Moncrieff J, Jureidini J, et al. A critique of the international consensus statement on ADHD. Clin Child Fam Psychol Rev. 2004;7(1):59–9. http://europepmc.org/abstract/MED/15119688 https://doi.org/10.1023/b:ccfp.0000020192.49298.7a. doi: 10.1023/b:ccfp.0000020192.49298.7a.
8. National Institute of MH. NIH consensus development conference on diagnosis and treatment of attention deficit hyperactivity disorder: November 16-18, 1998, william H. natcher conference center, national institutes of health, bethesda, maryland. National Institutes of Health, Continuing Medical Education; 1998.
9. Tough P. Have we been thinking about ADHD all wrong? The New York Times Web site. https://www.nytimes.com/2025/04/13/magazine/adhd-medication-treatment-research.html. Updated 2025. Accessed March 22, 2026.
10. Schwarz A. The selling of attention deficit disorder. 2013;14.
11. Blech Jö. Melancholy without shame (in german). 2012.
12. Eisenberg L, Psychopharmacol JC. Commentary with a historical perspective by a child psychiatrist: When “ADHD” was the “brain-damaged child”. 2007.
13. Saul R. ADHD does not exist: The truth about attention deficit and hyperactivity disorder. HarperCollins; 2014. https://books.Google Scholar.co.il/books?id=TZx_AQAAQBAJ.
14. Spiegel. What about tutoring instead of pills? interview with jerome kagan. Spiegel.Last retrieved on 27.6.21 from: https://www.spiegel.de/international/world/child-psychologist-jerome-kagan-on-overprescibing-drugs-to-children-a-847500.html. 2012.
15. Armstrong T. The myth of the ADHD child, revised edition: 101 ways to improve your child’s behavior and attention span without drugs, labels, or coercion. Penguin; 2017.
16. Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: A cross-sectional mega-analysis. The Lancet Psychiatry. 2017;4(4):310–319.
17. Batstra L, Meerman St, Conners K, Frances A. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. The Lancet Psychiatry. 2017;4(6):439. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30107-4/fulltext. Accessed Aug 25, 2026. doi: 10.1016/S2215-0366(17)30107-4.
18. Simons P. Lancet psychiatry’s controversial ADHD study: Errors, criticism, and responses. 2017. https://www.madinamerica.com/2017/05/lancet-psychiatrys-controversial-adhd-study-errors-criticism-responses/. Accessed Aug 25, 2026.
19. Ophir Y. Evidence that the diagnosis of ADHD does not reflect a chronic bio-medical disease. Ethical Human Psychology and Psychiatry. 2022;23(2):100–126. https://connect.springerpub.com/content/sgrehpp/23/2/100. doi: 10.1891/EHPP-2021-0001.
20. Frances A. Containing the adult ADHD fad — with a rejoinder from ChatGPT. 2023.
21. Kazda L, Bell K, Thomas R, McGeechan K, Sims R, Barratt A. Overdiagnosis of attention-deficit/hyperactivity disorder in children and adolescents: A systematic scoping review. JAMA Network Open. 2021;4(4):e215335. https://doi.org/10.1001/jamanetworkopen.2021.5335. doi: 10.1001/jamanetworkopen.2021.5335.
22. Davidovitch M, Shmueli D, Rotem RS, Bloch AM. Diagnosis despite clinical ambiguity: Physicians’ perspectives on the rise in autism spectrum disorder incidence. BMC Psychiatry. 2021;21(1):150. https://doi.org/10.1186/s12888-021-03151-z. doi: 10.1186/s12888-021-03151-z.
23. Maturo A. The medicalization of education: ADHD, human enhancement and academic performance. Italian Journal of Sociology of Education. 2013;5(3).
24. Searight HR, McLaren AL. Attention-deficit hyperactivity disorder: The medicalization of misbehavior. Journal of Clinical Psychology in Medical Settings. 1998;5(4):467–495.
25. O’Nions E, El Baou C, John A, et al. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: Matched cohort study. The British Journal of Psychiatry. 2025:1–8. https://www.cambridge.org/core/product/30B8B109DF2BB33CC51F72FD1C953739. doi: 10.1192/bjp.2024.199.
26. Ophir Y. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: Matched cohort study: Commentary, ophir. The British Journal of Psychiatry. 2025;227(3):648–649. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/abs/life-expectancy-and-years-of-life-lost-for-adults-with-diagnosed-adhd-in-the-uk-matched-cohort-study-commentary-ophir/2751A56CF0B5AEFD3AEF46F52F6FDF59. Accessed Sep 22, 2025. doi: 10.1192/bjp.2025.122.
27. Nigg JT. Attention-deficit/hyperactivity disorder and adverse health outcomes. Clin Psychol Rev. 2013;33(2):215–228.
28. Amour MDS, O’Leary DD, Cairney J, Wade TJ. What is the effect of ADHD stimulant medication on heart rate and blood pressure in a community sample of children? Canadian Journal of Public Health. 2018;109(3):395–400. https://doi.org/10.17269/s41997-018-0067-0. doi: 10.17269/s41997-018-0067-0.
29. Chan M, Chan JJ, Wright JM. Effect of amphetamines on blood pressure. Cochrane Database of Systematic Reviews. 2025(3). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007896.pub4/full. Accessed Aug 13, 2026. doi: 10.1002/14651858.CD007896.pub4.
30. Tadrous M, Shakeri A, Chu C, et al. Assessment of stimulant use and cardiovascular event risks among older adults. JAMA Network Open. 2021;4(10):e2130795. https://doi.org/10.1001/jamanetworkopen.2021.30795. doi: 10.1001/jamanetworkopen.2021.30795.
31. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012;169(2):178–185. https://doi.org/10.1176/appi.ajp.2011.11010125. doi: 10.1176/appi.ajp.2011.11010125.
32. Mosholder AD, Taylor L, Mannheim G, Ortendahl L, Woodworth TS, Toh S. Incidence of heart failure and cardiomyopathy following initiation of medications for attention-deficit/hyperactivity disorder: A descriptive study. J Clin Psychopharmacol. 2018;38(5). https://journals.lww.com/psychopharmacology/Fulltext/2018/10000/Incidence_of_Heart_Failure_and_Cardiomyopathy.17.aspx.
33. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166(9):992–1001. https://doi.org/10.1176/appi.ajp.2009.09040472. doi: 10.1176/appi.ajp.2009.09040472.
34. Shoval G, Visoki E, Moore TM, et al. Evaluation of attention-deficit/hyperactivity disorder medications, externalizing symptoms, and suicidality in children. JAMA network open. 2021;4(6):e2111342.
35. Bruno S, Kiki C, Katia V. General practice database on mortality in adults on methylphenidate: Cohort study. BMJ Open. 2022;12(8):e057303. http://bmjopen.bmj.com/content/12/8/e057303.abstract. doi: 10.1136/bmjopen-2021-057303.
36. Arnold LE, Bozzolo DR, Hodgkins P, et al. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: Continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr Med Res Opin. 2010;26(1):129–137.
37. Hoare P, Remschmidt H, Medori R, et al. 12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry. 2005;14:305–309.
38. MHRA. Package leaflet: Concerta® XL 27 mg prolonged-release tablets. 2024.
39. O’Nions E, Stott J. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: Matched cohort study: Commentary, O’Nions et al. The British Journal of Psychiatry. 2026;228(1):85–85. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/abs/life-expectancy-and-years-of-life-lost-for-adults-with-diagnosed-adhd-in-the-uk-matched-cohort-study-commentary-onions-et-al/E4643CE4E802FFD1D1BB0DE39ACC5EAF. Accessed Aug 23, 2026. doi: 10.1192/bjp.2025.10387.
40. Li L, Zhu N, Zhang L, et al. ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA. 2024;331(10):850–860. https://doi.org/10.1001/jama.2024.0851. Accessed Mar 23, 2025. doi: 10.1001/jama.2024.0851.
41. APA. Diagnostic and statistical manual of mental disorders – third edition (DSM-III). American Psychiatric Association (APA); 1980.
42. Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. Journal of Clinical Child & Adolescent Psychology. 2018;47(2):199–212. https://doi.org/10.1080/15374416.2017.1417860. doi: 10.1080/15374416.2017.1417860.
43. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United states, 2003–2011. Journal of the American Academy of Child & Adolescent Psychiatry. 2014;53(1):34–46.
44. Merzon E, Manor I, Rotem A, et al. ADHD as a risk factor for infection with covid-19. Journal of Attention Disorders. 2020;25(13):1783–1790. https://doi.org/10.1177/1087054720943271. doi: 10.1177/1087054720943271.
45. Pearson H. ADHD diagnoses are growing. what’s going on? Nature. 2025;647(8091):836–840. https://www.nature.com/articles/d41586-025-03855-2. Accessed Dec 12, 2025. doi: 10.1038/d41586-025-03855-2.
46. Cortese S, Daley D, Hollis C, et al. ADHD (over) diagnosis: Fiction, fashion and failure. The British Journal of Psychiatry. 2026:1–4. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/adhd-over-diagnosis-fiction-fashion-and-failure/1163426C23804A7049FE35D940EA938C. Accessed Mar 8, 2026. doi: 10.1192/bjp.2026.10546.
47. Frisira E, Holland J, Sayal K. Systematic review and meta-analysis: Relative age in attention-deficit/ hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry. 2024. https://doi.org/10.1007/s00787-024-02459-x. doi: 10.1007/s00787-024-02459-x.
48. Davis TO. Conceptualizing psychiatric disorders using ‘four d’s’ of diagnoses. The Internet Journal of Psychiatry. 2009;1(1):1.

The post ADHD UK Cannot Hide the Flawed Science Behind the Diagnosis and Its Treatment appeared first on Mad In America.

 

IPAK-EDU is grateful to Mad In America as this piece was originally published there and is included in this news feed with mutual agreement. Read More